Table 1.
Characteristics at study entry and at follow-up, by sex and among all subjects.
| Characteristics | At study entry (1986–2001) |
At follow-up (2012–2014) |
||||
|---|---|---|---|---|---|---|
| By sex |
By sex |
|||||
| Women N = 495 |
Men N = 397 |
All N = 892 |
Women N = 495 |
Men N = 397 |
All N = 892 |
|
| Mean (SD) pre-bronchodilator FEV1 in Liters | 2.84 (0.55) | 3.73 (0.82) | 3.24 (0.81) | 2.40 (0.63) | 3.12 (0.84) | 2.72 (0.81) |
| Mean (SD) pre-bronchodilator FEV1% of predicted | 90.2 (12.5) | 86.6 (14.9) | 88.6 (13.8) | 90.3 (15.4) | 83.1 (16.4) | 87.1 (16.2) |
| Mean (SD) number of years of follow-up | 18.2 (4.2) | 18.7 (4.4) | 18.4 (4.3) | |||
| Mean (SD) age (years) | 39.6 (11.7) | 40.6 (11.1) | 40.0 (11.5) | 57.9 (12.5) | 59.3 (11.7) | 58.5 (12.2) |
| Min-max age (years) | 19–70 | 19–69 | 19–70 | 33–92 | 32–92 | 32–92 |
| Mean (SD) BMI | 25.1 (4.6) | 26.1 (3.4) | 25.6 (4.1) | 28.2 (5.4) | 28.9 (4.4) | 28.5 (5.0) |
| Family history of asthma | 44.8% | 36.8% | 41.3% | |||
| Allergic sensitization | N/A | 26.8% | 42.9% | 33.9% | ||
| OCS use last 12 months | N/A | 2.2% | 1.3% | 1.7% | ||
| ICS use last 12 months | 10.9% | 12.8% | 11.8% | 48.1% | 38.3% | 43.7% |
| Never-smoker | 47.1% | 43.1% | 45.3% | 50.3% | 46.3% | 48.5% |
| Former smoker | 25.1% | 31.7% | 28.0% | 36.4% | 43.3% | 39.5% |
| Current smoker | 27.9% | 25.2% | 26.7% | 13.3% | 10.3% | 12.0% |
| Mean (SD) number of pack years of smokinga | N/A | 14.3 (14.2) | 21.3 (17.3) | 17.5 (16.0) | ||
| VGDF exposure | N/A | 21.0% | 62.9% | 39.7% | ||
Data presented as column % unless otherwise stated, Allergic sensitization = Positive on Phadiatop (>0.35 kU/L), SD = Standard deviation.
VGDF = vapors, gas, dust or fumes, L = liters, pp = %of predicted, BMI = body Mass Index.
N/A = Data not available, ICS = Inhaled corticosteroid, OCS = Oral corticosteroid.
a
Among former and current smokers